Further, tumor-derived platelets biomarkers, as KLK3, FOLH1, and NPY, enable prediction after abiraterone therapy in castration resistant prostate cancer (CRPC) and KLK2, KLK3, and FOLH1 were associated with short OS [67]. The gene discussed is KLK3; the disease is neoplasm.